Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial

Edmond M. Kwan; Sarah W.S. Ng; Sofie H. Tolmeijer; Louise Emmett; Shahneen Sandhu; James Buteau; Amir Iravani; Anthony M. Joshua; Roslyn J. Francis; Vinod Vijay Subhash; Sze-Ting Lee; Andrew M. Scott; Andrew Martin; Martin R. Stockler; Gráinne Donnellan; Matti Annala; Cameron Herberts; Ian D. Davis; Michael S. Hofman; Arun Azad; Alexander W. Wyatt

doi:10.1038/s41591-025-03704-9

Related publications

Article2021

177Lu-PSMA-617 versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer: a randomised, open-label, phase 2 trial (TheraP)

Michael S. Hofman, Louise Emmett, Amir Iravani, Shahneen Sandhu, Anthony M. Joshua, David A. Pattison, Jeffrey C. Goh, Ian Kirkwood, Thean Hsiang Tan, Roslyn J. Francis, Siobhan Ng, Natalie Rutherford, Craig Gedye, Andrew M. Scott, Sze-Ting Lee, Andrew Weickhardt, Shakher Ramdave, Edmond M. Kwan, Arun Azad, W A Macdonald, Andrew D. Redfern, Alison Y. Zhang, Martin R. Stockler, Andrew Martin, Ian D. Davis

Article2021

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

Michael S. Hofman, Louise Emmett, Shahneen Sandhu, Amir Iravani, Anthony M. Joshua, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, Ian Kirkwood, Siobhan Ng, Roslyn J. Francis, Craig Gedye, Natalie Rutherford, Andrew Weickhardt, Andrew M. Scott, Sze-Ting Lee, Edmond M. Kwan, Arun Azad, Shakher Ramdave, Andrew D. Redfern, W A Macdonald, Alex Guminski,

Article2023

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

Michael S. Hofman, Louise Emmett, Shahneen Sandhu, Amir Iravani, James Buteau, Anthony M. Joshua, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, Ian Kirkwood, Siobhan Ng, Roslyn J. Francis, Craig Gedye, Natalie Rutherford, Andrew Weickhardt, Andrew M. Scott, Sze-Ting Lee, Edmond M. Kwan, Arun Azad, Shakher Ramdave, Andrew D. Redfern,

Article2019

Results of a 50 patient single-center phase II prospective trial of Lutetium-177 PSMA-617 theranostics in metastatic castrate-resistant prostate cancer.

Michael S. Hofman, John Violet, Rodney J. Hicks, Justin Ferdinandus, Sue Ping Thang, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Timothy Akhurst, Jennifer Mooi, Christina Guo, Ben Tran, Price Jackson, Mark Scalzo, Peter Eu, Scott Williams, Shahneen Sandhu

Article2022

Improvements in symptoms related to bone metastasis in recipients of Lutetium-177 PSMA-617 for prostate cancer.

Brian D. Gonzalez, Naomi C. Brownstein, Wenyi Fan, Adam P. Dicker, Laura B. Oswald, Haryana M. Dhillon, Heather Jim, Shahneen Sandhu, Scott T. Tagawa, Scott Williams, Michael S. Hofman